RXRX vs RLAY
RXRX and RLAY side by side — valuation & fundamentals (public data).
Key statistics
| Metric | RXRXRECURSION PHARMACEUTICALS, INC. | RLAYRelay Therapeutics, Inc. |
|---|---|---|
| Market cap | $2.38B | $3.78B |
| P/S | 33.2x | 250.4x |
| Revenue growth (YoY) | 26.9% | 53.4% |
| Earnings growth (YoY) | -39.1% | 18.1% |
| EBIT margin | -867.9% | -1971.6% |
| ROE | -71.2% | -31.1% |
| ROIC | -181.7% | — |
| 1y total return | -27.5% | +146.1% |
Figures from SEC filings · for reference only · not investment advice
$10,000 투자 성장: RXRX vs RLAY
| 지표 | RXRX | RLAY |
|---|---|---|
| 최종 가치 | $1.2K | $5.3K |
| 총수익률 | -87.8% | -47.0% |
| CAGR | -31.5% | -10.8% |
| 변동성 | 93.0% | 76.1% |
| 샤프 | -0.01 | 0.17 |
| 소르티노 | -0.02 | 0.26 |
| 최대 낙폭 | -93.1% | -94.7% |
공통 거래일 1394일 기준, 2021-04-16 → 2026-11-02 · 무위험수익률 4.16% (현재 단기 국채 금리, 고정 적용)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)